Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy-Reference-Cited by-同舟云学术

Self‐Activated Cascade‐Responsive Sorafenib and USP22 shRNA Co‐Delivery System for Synergetic Hepatocellular Carcinoma Therapy

Published:2021-01-15 Issue:5 Volume:8 Page:2003042
ISSN:2198-3844
Container-title:Advanced Science
language:en
Short-container-title:Adv. Sci.

Author:

Xu Shengjun¹²³^ORCID,Ling Sunbin¹²³,Shan Qiaonan²³,Ye Qianwei²³,Zhan Qifan²³,Jiang Guangjiang²³,Zhuo Jianyong²³,Pan Binhua²³,Wen Xue⁴,Feng Tingting⁵,Lu Haohao⁶,Wei Xuyong¹²³,Xie Haiyang³,Zheng Shusen²³⁷,Xiang Jiajia⁸,Shen Youqing⁸,Xu Xiao¹²³^ORCID

Affiliation:

1. Department of Hepatobiliary and Pancreatic Surgery Affiliated Hangzhou First People's Hospital Zhejiang University School of Medicine Hangzhou Zhejiang 310006 China

2. Department of Hepatobiliary and Pancreatic Surgery the First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China

3. NHC Key Lab of Combined Multi‐Organ Transplantation Hangzhou Zhejiang 310003 China

4. Department of Pathology the First Affiliated Hospital School of Medicine Zhejiang University Hangzhou Zhejiang 310003 China

5. Department of Abdominal Medical Oncology Zhejiang Cancer Hospital Hangzhou Zhejiang 310022 China

6. Department of Polymer Science and Engineering Zhejiang University Hangzhou Zhejiang 310027 China

7. Department of Hepatobiliary and Pancreatic Surgery Shulan (Hangzhou) Hospital Hangzhou Zhejiang 310000 China

8. Center for Bionanoengineering and Key Laboratory of Biomass Chemical Engineering of Ministry of Education College of Chemical and Biological Engineering Zhejiang University Hangzhou Zhejiang 310027 China

Funder

Natural Science Foundation of Zhejiang Province

National Natural Science Foundation of China

Publisher

Wiley

Subject

General Physics and Astronomy,General Engineering,Biochemistry, Genetics and Molecular Biology (miscellaneous),General Materials Science,General Chemical Engineering,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/advs.202003042

Reference43 articles.

1. Hepatocellular Carcinoma

2. Hepatocellular carcinoma: Current situation and challenge

3. Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival

4. Is the era of sorafenib over? A review of the literature

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements and application prospects of three-dimensional models for primary liver cancer: a comprehensive review;Frontiers in Bioengineering and Biotechnology;2023-12-21

2. A LIGHTFUL nanomedicine overcomes EGFR-mediated drug resistance for enhanced tyrosine-kinase-inhibitor-based hepatocellular carcinoma therapy;Biomaterials;2023-11

3. Insulin-induced gene 2 protects against hepatic ischemia–reperfusion injury via metabolic remodeling;Journal of Translational Medicine;2023-10-19

4. Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma;Materials Today Bio;2023-10

5. Transforming Cancer-Associated Fibroblast Barrier into Drug Depots to Boost Chemo-Immunotherapy in “Shooting Fish in a Barrel” Pattern;ACS Nano;2023-06-16